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Abstract
Objective: To describe the baseline characteristics in patients who chose placement of a LAP-BAND APH System (LBAP) and
participated in the Helping Evaluate Reduction in Obesity (HERO) Study across regions.
Patients and Methods: HERO is a five- year, prospective, multicenter, international study of patients with LBAP placement
between July 22, 2009 and January 31, 2011. In addition to baseline and peri-surgery clinical data, seven follow up visits are
scheduled at 3, 6 and 12 months, and annually through year five. Data collection included family and medical history,
clinical outcomes, laboratory data, health-related quality of life (HRQoL), productivity, healthcare resource utilization, and
adverse events.
Results: LBAP were placed in 1106 enrolled patients; 56.6% from the US, 26.3% from Europe, 7.1% from Canada, and 10.0%
from Australia. The majority were female (n = 877 (79.3%)) with a mean age of 43 years (s.d. = 11.4) and mean body mass
index of 45.1 kg/m2 (s.d. = 6.9). The most common comorbidities were hypertension (HTN) (overall = 42.9%) and diabetes
(overall 22.2%, with 27% from the US and 14% from Europe). Overall, less than 5% had a history of cardiovascular disease.
The prevalence rates of HTN, diabetes and cardiovascular disease were significantly (p,0.001) higher in men than in women
across all regions. Overall HRQoL also worsened with increasing BMI.
Conclusions: The HERO study is the first large, multinational and long-term registry with the LBAP. This study will provide
real-world outcomes data on LAGB that will help inform patient choice, clinician treatment strategies, and payer
reimbursement decisions.
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Introduction
Obesity is a global public health problem of epidemic
proportions, affecting 205 million men and 297 million women
over the age of 20 worldwide in 2008 [1]. Obesity has a profound
impact on increased risk for developing comorbid chronic diseases
and premature mortality [2,3]. Excess weight also imposes an
economic burden on individuals and health care systems,
including direct costs from health resource utilization and indirect
societal costs from absenteeism and workplace injuries, disability
payments, and decreased productivity [4–8].
Due to the notable clinical, economic and humanistic impact of
obesity, weight reduction is a critical goal for both patients and
clinicians. Bariatric surgery is one such weight reduction option for
a subset of obese individuals. The choice by patients and their
physicians to use a surgical option for weight loss is influenced by
various factors including weight, comorbidity, gender, age,
geography, safety and reimbursement. Bariatric surgery typically
results in greater and more sustainable weight loss compared to
non-surgical approaches [9]. In addition, a growing body of
evidence suggests that modest sustained weight loss achieved
through bariatric surgery can improve health outcomes, including
improving co-morbid conditions, in surgery-eligible obese indi-
viduals more successfully than diet, exercise, and/or medications
[10]. As a result, multiple professional organizations including the
American Diabetes Association, the American Association of
Clinical Endocrinologists and governmental health agencies such
as the National Institute for Clinical Excellence (NICE) recom-
mend bariatric surgery as an option for adults with Body Mass
Index (BMI) $40 kg/m2 or (BMI) .35 kg/m2 with one or more
comorbid conditions [11,12,13,14] and for any patient with a BMI
$40 kg/m2 [12,13]. Bariatric procedures are now mostly done
laparoscopically and have widely-acceptable safety profiles, with
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adjustable gastric bands typically being recognized as the safest of
available procedures [15–17].
Gastric banding was first used in the early 1990’s. The LBAP,
typically placed laparoscopically, is the latest generation of
adjustable gastric banding systems, with improvements designed
to enhance the safety and efficacy of the device [18]. In the United
States (US), these new generation adjustable gastric bands were
approved in 2006 for use in patients with a BMI of 40 kg/m2, or
35 or greater with an existing comorbidity; similar approvals for
other countries in the study include Canada in 2006, the EU in
2005, and Australia in 2003. In 2011, the Food and Drug
Administration (FDA) approved an expanded the indication for
the LBAP, lowering the BMI restriction to include adults with
BMI over 30 kg/m2 who have at least one obesity-related
comorbid condition, such as diabetes or heart disease [18].
Given the many options available and limited duration of
randomized trials, there is growing interest in examining the long-
term safety and other outcomes for those who undergo bariatric
surgery, including LBAP. These outcomes extend beyond weight
loss to include changes in obesity-related medical conditions,
health resource utilization, and health-related quality of life
(HRQoL). With respect to the LBAP, however, there are also
gaps in knowledge about the long-term benefits and risks of this
device when used with the latest surgical techniques in a more
heterogeneous patient population. Although the literature sum-
marizes adverse events and the impact of banding on weight loss,
many of these citations are case studies or single site convenience
samples, and may use older bands or obsolete surgical techniques
[19–21].
To provide more current and relevant information to decision
makers, the Helping Evaluate Reduction in Obesity (HERO)
Study (NCT00953173) is designed to provide real-world effec-
tiveness and safety evidence of the LBAP. The objectives of this
manuscript are to provide a detailed description of the HERO
study design and patient characteristics in the participating
regions.
Methods
The HERO Study was designed to: (1) evaluate outcomes
among LBAP recipients in a real world setting; (2) describe the
prevalence of and/or changes from baseline comorbidities after
placement of the LBAP; (3) assess changes in HRQoL measures;
(4) quantify changes in healthcare expenditures; and (5) monitor
the long term safety of the device by summarizing Adverse Events
(AEs).
Study Design
The HERO study screened 1,153 patients from 29 sites.
Sequential enrollment, an accepted hallmark of quality for
registries, [22] was used to reduce the potential for bias associated
with selective enrollment. The study was designed to incorporate
multi-country experience, with physicians and patients from
Australia (AUS), Canada (CA), Europe or EU countries (Belgium,
Italy, the UK), and the US. The decision to have the LPAP
procedure was made independently of this study and prior to
patient enrollment in this study. Patients provided written
informed consent before enrolling into the HERO study. The
study was approved by the Ethics Committees and Institutional
Review Boards appropriate for each country. They included:
N Calvary Health Care Adelaide (CHCA) Human Research
Ethics Committee.
N Melbourne Clinic Research Ethics Committee.
N Commissie Medische Ethiek UZ Brussel.
N Aizenda USL 11 Empoli.
Table 1. Patient Disposition, by Region.
Total US Europea Canada Australia
Patients screened for eligibility 1153 644 300 80 129
Screening failures 18 3 7 0 8
Patient did not meet BMI eligibility criteria 7 (38.9%) 1 (33.3%) 4 (57.1%) 0 (0.0%) 2 (25.0%)
No expectation of compliance with the
study plan
2 (11.1%) 1 (33.3%) 1 (14.3%) 0 (0.0%) 0 (0.0%)
Patient had prior bariatric surgery 1 (5.6%) 1 (33.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Patient did not provide IC 8 (44.4%) 0 (0.0%) 2 (28.6%) 0 (0.0%) 6 (75.0%)
Withdrew prior to baseline 12 1 0 0 11
Subject withdrew consent 5 (41.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (45.5%)
Subject did not undergo the surgery to
implant LAP-BAND APH System
2 (16.7%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 1 (9.1%)
Subject did not comply with the ICF/CIP
requirements
1 (8.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (9.1%)
Other 4 (33.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (36.4%)
Withdrew prior to surgery 17 14 2 1 0
Subject did not undergo the surgery to
implant LAP-BANDAPH System
16(94.1%) 13(92.9%) 2 (100.0%) 1 (100.0%) 0 (0.0%)
Unsuccessful LAP-BAND APH System
implantation
1 (5.9%) 1 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Patients undergoing surgery for
LAP-BAND APH
1106 626 291 79 110
aEuropean countries included Belgium, Italy and UK.
doi:10.1371/journal.pone.0078971.t001
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N Universita degli studi di Napoli ‘‘Federico II’’ Comitato Etico
per le Attivita Biomediche (Ethics Committee for the
Biomedical Activities) ‘‘Carlo Romano’’.
N Comitato Etico per la Sperimentazione Clinica della Provincia
di Vincenza.
N Birmingham, East, North, and Solihull Research Ethics
Committee.
N Sussex NHS Research Consortium.
N Derby Hospitals NHS Foundation Trust.
N Quorum IRB.
N IRB of Regional West Medical Center.
N BRANY IRB.
N Scripps IRB.
Inclusion and exclusion criteria are consistent with the original
product labeling in the participating countries (i.e., prior to the
lower BMI approval in 2011) such that adults with a BMI
$40 kg/m2 or a BMI $35 kg/m2 with one or more severe
comorbid conditions were included in the study. Patients were
excluded if they had Type 1 diabetes or had undergone prior
bariatric surgery.
Data Collection
Study data are collected pre-operatively (no more than 8 weeks
prior to surgery), peri-operatively, and post-operatively at 3, 6 and
12 months (64 weeks), and at 2, 3, 4, and 5 years (68 weeks).
These data collection visits are scheduled to comport with routine
care and to allow for the flexibility in scheduling that is common to
observational research. In the event that a patient misses a follow-
up visit, a site coordinator will phone the patient to capture key
safety data. If the site coordinator is unable to reach the patient
after three attempts at different times of the day, a registered letter
(i.e., requiring signature as proof of delivery) will be sent to the
Table 2. Key Demographic Variables by Region.
Demographics
Overall
(N=1106) US (N=626) Europea (N=291) Canada (N=79) Australia (N=110)
Age, years Mean (sd) 43.1 (11.4) 43.9 (11.4) 41.5 (11.4) 45.1 (10.9) 41.7 (11.7)
Gender, n (%)
Female 877 (79%) 499 (80%) 230 (79%) 64 (81%) 84 (76%)
Male 229 (21%) 127 (20%) 61 (21%) 15 (19%) 26 (24%)
Education
Less than High School 86 (8%) 1 (0%) 78 (27%) 2 (3%) 5 (5%)
High School Diploma 616 (56%) 360 (58%) 159 (55%) 29 (37%) 68 (62%)
University degree 401 (36%) 265 (42%) 51 (18%) 48 (61%) 37 (34%)
No Response 3 0 3 0 0
Employment status
Full-time 653 (61%) 414 (67%) 131 (49%) 52 (66%) 56 (51%)
Part-time 111 (10%) 41 (7%) 41 (15%) 6 (8%) 23 (21%)
Freelancer 39 (4%) 13 (2%) 17 (6%) 5 (6%) 4 (4%)
Currently not working 270 (25%) 151 (24%) 76 (29%) 16 (20%) 27 (25%)
No Response 33 7 26 0 0
Marital status
Married 672 (61%) 374 (61%) 158 (54%) 45 (57%) 68 (62%)
Parental history of obesity
Yes 610 (57%) 374 (61%) 146 (54%) 32 (42%) 58 (55%)
No 454 (43%) 238 (39%) 124 (46%) 45 (58%) 47 (45%)
No Response 42 14 21 2 5
BMI (kg/m2)
Mean (sd) 45.1 (6.9) 45.4 (7.0) 45.2 (6.9) 45.1 (6.8) 43.6 (5.6)
Waist circumference, cm
Mean, sd 126.2 (16.8) 125.9 (17.8) 126.7 (16.8) 126.1 (14.1) 127.0 (13.3)
No response 5 3 2 0 0
Duration of obesity, years
Mean, sd 18.2 (10.7) 18.7 (10.8) 17.3 (10.3) 21.2 (11.4) 15.3 (9.4)
Unknown 230 112 73 7 38
Age became obese, years
Mean, sd 25.2 (11.8) 25.5 (12.1) 24.2 (11.0) 24.0 (11.2) 27.6 (12.1)
Unknown 230 112 73 7 38
aEuropean countries included Belgium, Italy and UK.
doi:10.1371/journal.pone.0078971.t002
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patient in an effort to obtain key safety data. The target retention
rate is 70% or better at five years.
All data are collected via a secure web-based data entry system
(Outcome SystemH, Quintiles Outcome, Cambridge, MA USA).
An electronic case report form (eCRF) is completed for each study
visit and is stored in a secure server in compliance with FDA 21
CFR Part 11 guidelines. Regular study monitoring is conducted,
with a target of achieving nearly 100% source data verification.
De-identified data are transferred via a secure SharePoint site to
the sponsor for data analyses.
Measurements of HERO Study
Medical chart reviews of demographic information such as age,
gender, education level, and employment status, family and
medical history were collected at baseline. Concomitant medica-
tion usage was retrieved from medical charts at baseline and will
be collected at each scheduled visit. Weight, height, and waist
circumference were measured at baseline and are obtained at each
of the scheduled physician visits.
Peri-surgery data included procedure details, device information
(serial number), and any adverse events.
Laboratory evaluations which included hemoglobin A1c
(HbA1c), fasting glucose, fasting lipid profile (total cholesterol,
high density lipoprotein [HDL], low density lipoprotein [LDL],
and triglycerides were collected at baseline and will be collected at
yearly follow up visits.
Patient reported outcomes, collected at baseline and at each
scheduled follow-up visit, are used to assess HRQoL and work
productivity. These instruments included the Short Form-12 (SF-
12H) [23], the European Quality of Life –5 Dimensions (EQ-
5DTM) [24], the Impact of Weight on Quality of Life – Lite
(IWQOL-Lite) [25], and the Work Productivity and Activity
Impairment Questionnaire General Health version 2.0 (WPAI)
[26], all of which have been validated.
SF-12. The 12-Item Short Form Health Survey is a general
health status measure. It is self-administered and assesses 8
domains: physical functioning, role limitations due to physical
health, bodily pain, general health perceptions, vitality, social
functioning, role limitations due to emotional problems, and
mental health. Summary Mental and Physical Component scores
are generated using a proprietary algorithm supplied by the
instrument developers. A 4-week recall period is used and the
scoring method used normalized responses to 50610, with higher
scores indicating better health status [23].
EuroQol (EQ-5D). The EQ-5D is a generic health-related
quality of life measure. It is self-administered and has 5 dimensions
assessing mobility, self-care, usual activities, pain/discomfort,
anxiety/depression. It also includes a visual analog scale that asks
respondents to rate their current health from 0–100, with 0
representing death and 100 indicating perfect health. The 5-item
questionnaire can also be transformed to a societal-based utility
score, ranging from 0–1, with higher scores reflecting better health
status, as recommended by its authors [24].
Impact of Weight on Quality of Life – Lite (IWQOL-
Lite). The IWQOL-Lite is the shortened version of IWQOL, an
obesity-specific QOL instrument consisting of 31 items and 5




(N=291) Canada (N=79) Australia (N=110)
Hypertension, N (%) 474 (42.9%) 310 (49.5%) 99 (34.0%) 31 (39.2%) 34 (30.9%)
Number of years with
hypertension, Mean (sd)
7.7 (7.6) 8.2 (8.1) 6.9 (5.9) 7.3 (5.7) 6.1 (7.5)
Any Hypertension
Medication Usage, N (%)
391 (82.5%) 259 (83.5%) 74 (74.7%) 30 (96.8%) 28 (82.4%)
Type 2 Diabetes, N (%) 245 (22.2%) 169 (27.0%) 41 (14.1%) 18 (22.8%) 17 (15.5%)
Number of years with Type 2 Diabetes, mean (sd)
Overall 7.0 (6.2) 6.9 (6.4) 8.5 (4.9) 7.6 (7.1) 3.9 (3.1)
Patients treated with insulin 11.7 (6.9) 11.5 (7.5) 12.9 (3.9) 16.1 (7.4) 7.1 (3.9)
Patients treated without insulin 5.5 (4.8) 5.3 (5.1) 7.3 (4.3) 5.1 (4.9) 2.8 (1.9)
Anti-Diabetic Medication Usageb, N (%)
Treated with Insulin 65 (26.5%) 47 (27.8%) 10 (24.4%) 4 (22.2%) 4 (23.5%)
Treated with oral medication 186 (75.9%) 125 (74.0%) 35 (85.4%) 12 (66.7%) 14 (82.4%)
Treated with diet 84 (34.3%) 60 (35.5%) 4 (9.8%) 12 (66.7%) 8 (47.1%)
Without treatment 7 (2.9%) 6 (3.6%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Unknown 1 (0.4%) 1 (0.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Cardiovascular Disease, N (%) 49 (4.4%) 33 (5.3%) 8 (2.7%) 5 (6.3%) 3 (2.7%)
Number of years with any one of the
cardiovascular disease, Mean (sd)
6.2 (10.1) 6.5 (11.1) 4.1 (5.0) 4.9 (5.7) 9.6 (16.0)
Hyperlipidemia treated with lipid lowering agents, N (%)
1 Med 200 (18.1%) 124 (19.8%) 32 (11.0%) 22 (27.8%) 22 (20.0%)
$2 Meds 29 (2.6%) 25 (4.0%) 2 (0.7%) 2 (2.5%) 0 (0.0%)
Total 229 (20.7%) 149 (23.8%) 34 (11.7%) 24 (30.3%) 22 (20.0%)
aEuropean countries included Belgium, Italy and UK.
bPatients may be on multiple anti-diabetic medications. The total proportion will not sum up to 100%.
doi:10.1371/journal.pone.0078971.t003
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domains: Physical Function (11 items), Self-Esteem (7 items),
Sexual Life (4 items), Public Distress (5 items), and Work (4 items).
A domain score can be calculated by summing all items within that
domain and subsequent transformation to a score between 0 and
100. A total score can be obtained by summing scores for all 31
items. Lower scores indicate a better QOL [25].
Work Productivity and Activity Impairment (WPAI). The
WPAI yields scores for four domains: Absenteeism (work time
missed) with number of hours missed from work because of their
health problems, presenteeism (impairment at work/reduced on-
the-job effectiveness) or how much did health problems affect
productivity while working, work productivity loss (overall work
impairment/absenteeism plus presenteeism), and activity impair-
ment (non-work related). WPAI outcomes are expressed as
impairment percentages, with higher numbers indicating worse
outcomes [26].
Changes in healthcare expenditures, such as indirect cost, over
time will be derived using the WPAI scores to estimate cost to
employers based on amount of work days missed. In addition,
changes in cost from any decreased use of medications for
hypertension and/or diabetes medication can be estimated by
reported changes in use of anti-hypertensive and anti-diabetic
medications at baseline vs. follow up visits.
Food intake, eating patterns, target weight, and satisfaction with
weight loss and with the benefits provided by LBAP, are also
measured at baseline and annually.
Throughout the study, AEs are captured by asking patients
about any device related complications that may have occurred
and by investigators’ evaluation at each annual visit.
Table 4. Baseline Comorbidities by Gender.
Overall (N=1106) Male (N=229) Female (N=877) P-Value
Hypertension, N (%) 474 (42.9%) 310 (49.5%) 99 (34.0%) 31 (39.2%)
Number of Years with Hypertension, Mean (sd) 7.7 (7.6) 8.4 (8.1) 7.4 (7.3) .27
Hypertension Medication Usage, N (%) 391 (82.5%) 106 (83.5%) 285 (82.1%) .79
Type 2 Diabetes, N (%) 245 (22.2%) 71 (31.0%) 174 (19.8%) .001
Number of Years with Type 2 Diabetes, Mean (sd)
Overall 7.0 (6.2) 6.4 (4.7) 7.2 (6.6) .39
Patients treated with insulin 11.7 (6.9) 9.8 (3.8) 12.5 (7.8) .18
Patients treated without insulin 5.5 (4.8) 5.0 (4.3) 5.6 (5.0) .48
Anti-Diabetic Medication Usage, N (%)
Treated with insulin 65 (26.5%) 19 (26.8%) 46 (26.4%) .99
Treated with oral medication 186 (75.9%) 126 (72.4%) 126 (72.4%) .05
Treated with diet 84 (34.3%) 19 (26.8%) 65 (37.4%) .14
Without treatment 7 (2.9%) 0 (0%) 7 (4.0%) .19
Unknown 1 (0.4%) 0 (0%) 1 (0.6%) .99
Cardiovascular Disease, N (%) 49 (4.4%) 21 (9.2%) 28 (3.2%) .0001
Number of Years with Any One of the Cardiovascular
Diseases, Mean (sd)
6.2 (10.1) 9.5 (13.3) 3.5 (5.4) .06
Hyperlipidemia Problem, N (%) 229 (20.7%) 77 (33.6%) 152 (17.4%) .0001
Hyperlipidemia treated with lipid lowering agents, N (%)
1 Med 200 (18.1%) 66 (28.8%) 134 (15.3%) .59
$2 Meds 29 (2.6%) 11 (4.8%) 18 (2.1%) .66
doi:10.1371/journal.pone.0078971.t004
Table 5. Baseline Patient Reported Outcomes by BMI.
Baseline BMI













#35 (N = 14) 46.7 (7.00) 47.0 (10.78) 0.81 (0.148) 64.1 (16.37) 41.4 (33.25)
.35–#40 (N = 241) 39.6 (10.91) 42.3 (9.99) 0.74 (0.180) 50.4 (18.03) 48.5 (25.73)
.40–#45 (N = 389) 39.2 (11.09) 41.8 (9.40) 0.74 (0.174) 47.9 (18.64) 48.5 (26.85)
.45 (N = 462) 37.2 (11.50) 41.2 (10.14) 0.70 (0.207) 41.5 (20.19) 55.2 (28.98)
doi:10.1371/journal.pone.0078971.t005
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Information about AEs and rates of band explants will be used
to help establish its risk-benefit profile.
Descriptions of Baseline Variables Used in the HERO
Study
Duration of obesity (in years) was computed as the difference in
years between current age and age when patients became obese
(BMI .30). Presence of current conditions of T2DM, HTN, or
hyperlipidemia was separately coded. Subjects who had either
myocardial infarction, atrial fibrillation, peripheral vascular
disease, congestive heart failure or stroke in their medical history
were categorized as positive for cardiovascular disease. Duration of
T2DM, HTN, or any one cardiovascular disease in years was
computed as the difference between the LBAP implantation date
and the reported disease diagnosis date.
Proportion of anti-diabetes medication utilization was catego-
rized as insulin, oral medication, diet or no treatment. Use of anti-
hypertensive medication was binary coded. Proportions of subjects
treated with 1, 2 or more lipid lowering agents were also reported.
Statistical Analysis
Descriptive statistics were calculated for demographic, comor-
bid conditions, medication usage, and obesity measures, with basic
statistics given for the continuous data (number, mean, and
standard deviation), by regions. Regions were categorized as
follows: US, CA, AUS, and EU (UK, Italy, and Belgium). Analyses
were performed using SAS, Version 9.2 [27].
Results
Patient recruitment started in July 2009, and 1,153 patients
were screened for eligibility by January 31, 2011. There were 47
screen failures (Table 1). HERO was fully enrolled on January 31,
2011 with 1,106 patients implanted with LBAP; 626 (56.6%) from
US sites and 291 (26.3%) from European sites, 79 (7.1%) from
Canadian sites, and 110 (10%) from Australia sites.
As seen in Table 2, the study population (n = 1,106) is
predominantly female (79%), with a mean age of 43 years
611.4 (44–45 for US/CA and 41 for EU/AU). More than half
(56%) of the cohort have completed high school and over a third
(36%) have a university degree. At the time of study enrollment,
61% of patients were employed full-time and 61% were married.
A history of parental obesity was reported by 57% of the overall
cohort. The mean BMI at baseline was 45.1 kg/m2 66.9, and
mean waist circumference of 126.2 cm 616.8. On average,
patients were obese for 18 years 610.7 prior to implantation.
Regional differences in comorbidities at baseline were observed
(Table 3). The most common comorbidity was HTN (43%). One
in 2 obese patients had HTN in the US as compared with 1 in 3 in
EU, CA, or AUS. The mean duration since HTN diagnosis was
the longest for the US obese patients (8.2 years) as compared with
EU (6.9 years), CA (7.3 years) or AUS (7.5 years). The majority
(83%) of patients took hypertensive medications.
Nearly a quarter of the cohort (22.2%) had T2DM (27% in the
US, 14.1% in EU, 22.8% in CA, and 15.5% in AUS). Although
diabetes was more prevalent in the US sample, European obese
patients reported having had diabetes longer (mean 8.5 years) than
their counterparts in the US (mean 6.9 years), CA (mean
7.6 years) or AUS (mean 3.9 years). In addition, the mean
duration of diabetes history among patients taking insulin therapy
was longer than those not taking insulin therapy (11.7 years versus
5.5 years). Overall, 27% of the diabetes cohort was treated with
insulin. Three-quarters of the cohort took oral medications for
T2DM, with higher proportion of EU patients taking oral
medications (84.5%). Dietary monitoring was commonly practiced
in CA (67%) but less so in EU (9.8%).
In general, the prevalence of cardiovascular disease (CVD) was
low (4.4% overall) (Table 3). The mean duration of any one CVD
was 6.2 years, with the longest duration in AUS (9.6 years).
One in five obese patients reported having hyperlipidemia, with
the smallest proportion in EU (11.7%). Majority of them were
treated with only 1 lipid-lowering agent. Using more than one lipid
lowering agents was not common, and more US obese patients
(4%) reported using at least 2 lipid lowering agents (0.7% in EU,
2.5% in CA, and 0% in AUS).
Table 4 shows gender differences in comorbid conditions.
Across all obesity-related comorbidities, males were over-repre-
sented in HTN, T2DM, CVD and hyperlipidemia than females.
However, there were no gender differences in disease duration or
medication utilization patterns. Gender differences were not tested
for statistical significance within each region due to small sample
sizes for CA and AUS.
Overall patient reported outcomes decreased as BMI increased
by 5 kg/m2 increment (Table 5). Comparing BMI #35 and BMI
.45 kg/m2, mean PCS score decreased from 46.7 (67.00) to 37.2
(611.50) and mean MCS score went from 47.0 (610.78) to 41.2
(610.14) between those lowest and highest categories. Similarly,
comparing the lowest and highest categories of BMI, mean EQ-
5D scores were 0.81 (60.148) and 0.70 (60.207) and IWQoL total
scores were 64.1 (616.37) and 41.5 (620.19), respectively. Greater
impairment for non-work related activities as measured by WPAI
scores was also evident when the lowest and highest BMI
categories were compared (41.4% v 55.2%) (Table 5).
Discussion
The HERO study is designed to provide long term outcomes of
LBAP in ‘‘real-world’’ settings for a geographically diverse group
of patients. Observational study designs like this are increasingly
being used to report real world safety and outcomes data over
longer term periods than what is often possible in randomized
trials [28]. Further, HERO’s broad eligibility criteria enhance its
ability to provide descriptive information about the impact of
heterogeneity on outcomes.
Strengths of the HERO study include prospective follow-up of
its large patient pool, long-term follow-up on comorbid conditions,
a multi-country approach which improves the generalizability of
the data, use of validated instruments to assess HRQoL and
productivity, and measure of associated resource utilization. The
non-interventional design is also an asset since the study captures
real-world behavior in the absence of protocol-driven treatments
and behavioral supports [29]. However, this study also faces
several challenges. A main practical challenge concerns retention
of subjects over five years. In anticipation of this challenge,
procedures have been developed for follow-up for key outcomes by
telephone and mail for those who do not return to their surgeon
(see Methods Section.) In addition, it may be difficult to distinguish
whether the benefits and risks of the procedure can be
disentangled from other support characteristics such as frequency
of follow-up and nutritional counseling that contribute to
successful long-term weight control with any surgical weight-loss
procedure.
The demographic characteristic and comorbidity profile of the
HERO cohort is representative of those who opt for the procedure
as reported in the literature. Similar to the Nationwide Inpatient
Survey and The Bariatric Outcomes Longitudinal Database
(BOLD) registry and a meta-analysis of 612 international bariatric
surgery studies, the HERO cohort is predominantly female (80%),
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with a mean age between 44–47 years [30–32]. A body mass
trajectory study also revealed that weight gain is greater among
women than men suggesting they may be at greater risk of obesity-
related conditions without intensive weight management [33].
Women are also more likely to seek bariatric surgery than men,
who tend to be more motivated by other concurrent medical
conditions than weight outcomes [34].
Hypertension is the most common comorbidity in obesity,
followed by diabetes. The overall prevalence of HTN in this study
is also comparable to the 38 to 52% found in previous US and
multinational studies among bariatric surgery patients, [31,32,35–
38] although the Canadian Institute for Health Information
Discharge Abstract Database in 2002–2003 reported a lower rate
of 10% HTN and 10% diabetes among bariatric patients [39].
This is notable in that most of the patients are female and
relatively young compared to the overall hypertensive population.
Interestingly, regional differences in the prevalence of baseline
comorbidities were observed in the HERO study. US LBAP
cohort reported larger proportions of T2DM, HTN, and CVD, as
compared with the other three regions. This may be due to
variations in comorbid conditions requirements for coverage
across countries, or may be due to more aggressive use of surgical
weight loss in the US for obese patients with comorbidities.
Baseline HRQoL results from HERO corroborate previous
studies which have shown that the severely obese (BMI .40 kg/
m2) reported worse general health as well as emotional and social
impact compared to those with mild obesity (BMI 30–34.99 kg/
m2) [40–44].
High-quality long-term evidence on the risks and benefits of the
most up-to-date gastric banding devices and techniques will help
surgeons and patients make informed decisions about the
usefulness and desirability of this approach to control obesity
and its related comorbidities [45]. The consistency of information,
heterogeneity of patients, and long-term follow-up collected in the
HERO study will provide a large resource of systematic
naturalistic data on weight loss, changes in comorbidities, and
patient reported outcomes.
Findings from HERO will assist patients and physicians in
making better informed treatment decisions for obesity and its
related comorbidities, as well as provide meaningful data from a
robust and generalizable sample which should help to update
standards of practice for the treatment of obesity. Overall, these
data fill important gaps in knowledge about the effectiveness of
current surgical techniques as practiced in real-world settings, both
from the perspective of the physician and the patient. Additional
research questions to pursue include, but are not limited to,
regional differences in reduction of comorbidities over time and
how those differences may affect HRQoL.
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